Scinai Immunotherapeutics Ltd. (SCNI) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SCNI Revenue Growth
Revenue Breakdown (FY 2024)
SCNI's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
SCNI Revenue Analysis (2014–2025)
As of May 8, 2026, Scinai Immunotherapeutics Ltd. (SCNI) generated trailing twelve-month (TTM) revenue of $1.1 million, reflecting explosive growth of +36.1% year-over-year. The most recent quarter (Q2 2025) recorded $386,500 in revenue, up 0.0% sequentially.
Looking at the longer-term picture, SCNI's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $1.3 million in 2025, representing a new all-time high.
Revenue diversification analysis shows SCNI's business is primarily driven by License (100%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NVAX (-52.5% YoY), DYAI (-21.9% YoY), and IBIO (-20.0% YoY), SCNI has underperformed the peer group in terms of revenue growth. Compare SCNI vs NVAX →
SCNI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SCNICurrent | $1M | +36.1% | - | -575.3% | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% | |
 DYAI | $3M | -21.9% | +15.8% | -168.8% | |
 IBIO | $400,000 | -20.0% | -24.6% | -4650.5% | |
 VXRT | $237M | +726.7% | +125.8% | 7.6% | |
 MNOV | $409,657 | - | - | -3242.5% |
SCNI Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.3M | +99.2% | $-2,652,000 | -202.3% | $-7,542,000 | -575.3% |
| 2024 | $658K | - | $-580,000 | -88.1% | $-8,638,000 | -1312.8% |
| 2023 | $0 | - | $-512,675 | - | $-9,706,000 | - |
| 2022 | $0 | - | $-559,801 | - | $-11,061,000 | - |
| 2021 | $0 | - | $-747,649 | - | $-10,874,000 | - |
| 2020 | $0 | - | $-708,920 | - | $2.3M | - |
| 2019 | $0 | - | $0 | - | $-22,689,000 | - |
| 2018 | $0 | - | $0 | - | $-20,608,000 | - |
| 2017 | $0 | - | $0 | - | $-6,798,000 | - |
| 2016 | $0 | - | $0 | - | $-3,089,000 | - |
See SCNI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SCNI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SCNI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSCNI — Frequently Asked Questions
Quick answers to the most common questions about buying SCNI stock.
Is SCNI's revenue growth accelerating or slowing?
SCNI revenue is accelerating at +36.1% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $1M. Growth momentum has increased versus prior periods.
What is SCNI's long-term revenue growth rate?
Scinai Immunotherapeutics Ltd.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +36.1% is above this long-term average.
How is SCNI's revenue distributed by segment?
SCNI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.